ЦельCOVID-19, как и другие респираторные вирусы, имеет внелегочные проявления. В частности, воздействие вируса приводит к поражению сердечно-сосудистой системы (ССС), патофизиологические механизмы которого до конца не ясны; не сформировано полноценное понимание механизмов взаимодействия COVID-19 и ССС. В статье проанализированы современные представления о COVID-19, рассмотрены возможные звенья патогенеза, предпринята попытка систематизации патофизиологических механизмов поражения ССС и их осложнений, проанализирована связь с сердечно-сосудистой коморбидностью, описаны особенности патоморфологии и предположительный долгосрочный прогноз. Представленные сведения могут способствовать пониманию двустороннего взаимодействия кардиоваскулярных заболеваний и эффектов COVID-19 для разработки эффективных профилактических мер и принятия верного решения в выборе терапевтической тактики для пациента в рамках системного подхода.

ong-term consequences of COVID-19 remain the subject of active research interest. In this article the Post-COVID-19 syndrome (PCS) main features and symptoms are considered, its incidence and link with comorbidity is presented and the possible mechanisms are discussed. Due to the damage COVID-19 has on lungs, heart, brain and other systems, patients with PCS require multidisciplinary management.

Unified management plan and treatment strategy for COVID-19 patients are yet to be discovered. Many trials on COVID-19 interventions have been registered or are ongoing. In this article the results of large-scale clinical trials on COVID-19 treatment are presented, the potential mechanism of action of some drugs is discussed, the features of the main pharmacological and non-pharmacological therapeutic options for COVID-19 patients are described.

Lately due to the increase of childbearing age of women, high prevalence of cardiovascular diseases, and, presumably, due to the usage of some medications, there was an increase in myocardial infarction (MI) cases in pregnant women. Risk factors and pathophysiological mechanisms of MI in pregnant women differ from the general population, and are heterogeneous. Pregnancy and childbirth can be defined as ‘physiological stress’ for the cardiovascular system, which can cause MI. Abrupt changes in hemodynamics and increased coagulation state during pregnancy, in childbirth or in the early postpartum period can provoke sudden constriction (vasospasm) of a coronary artery (CA), as well as non-atherosclerotic spontaneous CA dissection, which leads to a critical decrease in the supply of oxygen to the heart muscle. The frequency of hemodynamically significant atherosclerosis of CA is also increasing. The incidence of maternal, perinatal mortality and obstetric complications is higher than in women without history of acute coronary syndrome. Over the past few decades, the diagnosis and treatment of myocardial infarction improved, the number of primary percutaneous coronary interventions in pregnant women increased, and there is now less inpatient mortality. However, due to the absence of large randomized clinical trials on the MI in pregnant women it is impossible to develop a unified algorithm for the management and preventive measures for this condition, thereby it is difficult to select an optimal treatment tactic, and hard to predict subsequent cardiovascular events. In this article we analyzed current data on MI during pregnancy, childbirth, and the postpartum period.